Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEA trial of switching to mesalazine monotherapy versus continuing thiopurines in older patients with ulcerative colitis in sustained remission
2025-524675-23-00Phase 4Authorised
- Sponsor
- GETECCU
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Salcrozine, azathioprine and mercaptopurine in autoimmune colitis (2 arms), sponsored by GETECCU. Primary endpoint: Biological recurrence. Planned start Jun 2026; status: authorised.
02
Drugs
Salcrozineazathioprinemercaptopurine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-524675-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524675-23-00.